Research programme: small molecule therapeutics - Quimatryx

Drug Profile

Research programme: small molecule therapeutics - Quimatryx

Alternative Names: DNA methyltransferase inhibitors - Quimatryx; DNMT inhibitors - Quimatryx; HDAC inhibitors - Quimatryx; HDAC2 selective inhibitor - Quimatryx; HDAC6 selective inhibitor - Quimatryx; Isoform selective HDAC inhibitor - Quimatryx; JMJ inhibitors - Quimatryx; JMJ2DC(GASC1) inhibitors - Quimatryx; LFA-1 integrin inhibitor - Quimatryx; Lymphocyte function-associated antigen-1 inhibitor - Quimatryx; Proteasome inhibitors - Quimatryx; QTX 100; QTX 125; QTX 153; QTX 200; QTX 300; QTX 400; Sirtuin inhibitors and activators - Quimatryx

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IkerChem
  • Developer Quimatryx
  • Class Antidementias; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors; Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Mantle-cell lymphoma; Multiple sclerosis
  • Discontinued Liver metastases

Most Recent Events

  • 15 Mar 2018 Quimatryx has patent protection for QTX 125 in USA, Europe, China, Mexico, Japan and Russia (Quimatryx pipeline, March 2018)
  • 15 Mar 2018 Preclinical trials in Mantle cell lymphoma in Spain (PO) (Quimatryx pipeline, March 2018)
  • 15 Mar 2018 Preclinical trials in Multiple sclerosis in Spain (PO) (Quimatryx pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top